Key Takeaways
- Samsung Electronics has acquired Xealth, a digital health prescription platform that integrates with electronic health records.
- Xealth will maintain its brand and leadership while enhancing patient care through digital health tools.
- This acquisition strengthens Samsung’s commitment to healthcare technology, building upon previous collaborations with AI firms for diagnostic solutions.
Acquisition Details
Samsung Electronics has finalized its acquisition of Xealth, a U.S.-based digital health prescription platform. First revealed in July, this agreement allows Xealth to continue operating under its distinct brand while retaining its leadership team. The platform enables healthcare providers to prescribe, deliver, and monitor digital health tools through electronic health records (EHR), aimed at improving patient care and boosting clinical efficiency.
Xealth’s suite of solutions includes multimedia patient education, digital clinical assessments, remote patient monitoring, and virtual care referrals, designed to support patients throughout their healthcare journey. A key feature of Xealth’s technology is its Digital Care SMART on FHIR app, which allows clinicians to prescribe and monitor digital health tools directly from EHR systems. This integration not only facilitates clinical decision support but also automates patient enrollment in digital programs where applicable.
The app can be accessed via EHR app stores and is designed to integrate smoothly into the provider’s workflow. By utilizing EHR data, Xealth seeks to enhance both digital care delivery and engagement among care teams and patients.
Dr. Hon Pak, senior vice president at Samsung’s Mobile eXperience Business, emphasized the collaborative aims of Samsung and Xealth in transforming the healthcare ecosystem to improve overall health outcomes. Mike McSherry, CEO of Xealth, expressed that this partnership with Samsung will enrich the patient experience and bridge the gap between home health monitoring and clinical decision-making.
This transaction aligns with Samsung’s increasing investment in healthcare technology, following its collaborations with South Korean AI firms Lunit and VUNO, which focused on integrating AI solutions into X-ray and radiography systems. Earlier this year, Xealth also received support from Morningside Ventures, aimed at improving the management and deployment of digital health formularies within health systems.
As the healthcare industry adapts to increasingly digital solutions, this acquisition positions Samsung and Xealth at the forefront of an evolving landscape, aiming to enhance patient care through innovative technology.
The content above is a summary. For more details, see the source article.
